Bayesian borrowing

R&D

Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.

News

After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.